Medicure Inc. (OTCMKTS:MCUJF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $7.25 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 10.69% from the company’s previous close.

According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “

Separately, ValuEngine raised shares of Medicure from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th.

Shares of Medicure (OTCMKTS:MCUJF) remained flat at $6.55 on Thursday. The company’s stock had a trading volume of 95 shares. The firm’s 50 day moving average price is $6.30 and its 200-day moving average price is $6.21. The firm has a market capitalization of $102.40 million, a price-to-earnings ratio of 6.00 and a beta of 0.55. Medicure has a 52 week low of $4.11 and a 52 week high of $7.96.

COPYRIGHT VIOLATION WARNING: “Medicure Inc. (MCUJF) Upgraded at Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/17/medicure-inc-mcujf-upgraded-at-zacks-investment-research.html.

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Get a free copy of the Zacks research report on Medicure (MCUJF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.